#ViiV Healthcare

An expert panel’s draft recommendation gives injectable PrEP an A grade, which will make the HIV prevention option more widely available.

The U.S. Business Action to End HIV coalition boosts public-private partnerships and spells out six ways companies can fight the epidemic.

The ViiV Healthcare grants are a key element of the company’s Risk to Reason HIV initiative guided by and for Black women.

Held in Puerto Rico, #2022USCHA highlighted HIV in Latino populations, language justice, storytelling, music and much more.

Gilead, ViiV, NMAC, HRC, NBJC, GLAAD and others offer $5.5 million in grants to help community groups respond to monkeypox.

Generic cabotegravir, an every-other-month injectable to prevent HIV, will arrive in select countries. WHO and Health Gap have opinions.

Cultural influencers take off their blindfolds to destigmatize HIV prevention in ViiV’s “Me in You, You in Me” campaign. [VIDEOS]

ViiV Healthcare’s Risk to Reasons initiative offers stigma-free language for discussing HIV and Black women. Apply now for grants.

The Women as the Face of AIDS Summit, organized by Iris House, also honored three trailblazing women working to end the HIV epidemic.

The approval makes this the first single-pill regimen containing dolutegravir available in a water-dispersible formulation.

Funded by ViiV Healthcare, the National AIDS Memorial’s award honors AIDS activist and poet Mary Bowman, who died at age 30.

Using the new dosing schedule, injectable cabotegravir and rilpivirine can be administered just six times a year.

Anika Noni Rose hosts Season 3 of ViiV Healthcare’s “Being Seen,” covering Black women’s views on stigma, bias, power, HIV and more.

Season 2 of ViiV’s podcast explores how queer Black men want to be seen—and how that relates to HIV stigma.

Injectable cabotegravir and rilpivirine are approved for people with viral suppression who would prefer monthly injections to daily pills.

A study analyzed how well people with HIV and their health care providers can navigate the experimental long-acting injectable Cabenuva.